Nephros Inc. NEPH
4.23
0.09
2.17%
as of 25 Sep
- Market cap
- $45.0M
- P/E
- 27.2×
Follow NEPH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
36.38 | 46.12 | 45.29 | 22.91 |
P/S ratio |
2.80 | 2.76 | 1.66 | 1.87 | |
P/FCF ratio |
19.35 | 34.07 | 0.00 | 0.00 | |
P/Operating CF |
507.02 | 225.16 | (18.99) | 56.92 | |
P/B ratio |
5.02 | 5.08 | 2.97 | 3.24 | |
Price to Tangible BV |
5.74 | 5.78 | 3.35 | 3.60 | |
EV/Sales |
2.55 | 2.51 | 1.49 | 1.68 | |
EV/EBITDA |
28.86 | 36.71 | 35.49 | 19.76 | |
EV/Operating CF |
16.85 | 28.67 | (81.90) | (52.71) | |
EV/FCF |
17.66 | 31.03 | (60.26) | (44.33) | |
Quick Ratio |
3.17 | 2.82 | 2.98 | 2.63 | |
Current Ratio |
4.34 | 4.06 | 4.55 | 4.07 | |
Net Debt/EBITDA |
(14.86) | (108.00) | (32.40) | (3.78) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.52 | 1.51 | 1.50 | 1.48 | |
Operating CF/Net income |
0.29 | 3.71 | (11.94) | 0.57 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
7.09% | 8.35% | 6.64% | 6.08% | |
Selling, General and Administrative Expense of Revenue |
46.79% | 48.97% | 48.37% | 40.19% | |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.09 | 0.08 | |
Share Based Compensation of Revenue |
1.47% | 1.67% | 1.15% | 1.01% | |
Graham Net Nets |
0.15 | 0.15 | 0.26 | 0.25 | |
Graham Number |
1.66 | 1.51 | 1.22 | 1.97 | |
Earnings Yield |
2.75% | 2.17% | 2.21% | 4.36% | |
Free Cash Flow Yield |
5.17% | 2.94% | (1.49%) | (2.03%) | |
Revenue per Share |
0.45 | 0.45 | 0.49 | 0.55 | |
Operating CF per Share |
0.01 | 0.02 | (0.16) | 0.06 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | 0.02 | (0.16) | 0.06 | |
Cash per Share |
0.49 | 0.51 | 0.38 | 0.43 | |
Shareholders Equity per Share |
0.94 | 0.96 | 1.00 | 1.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.94 | 0.96 | 1.00 | 1.10 | |
Free Cash Flow |
0.10 | 0.23 | (1.67) | 0.68 | |
Working Capital |
8.24 | 8.46 | 8.97 | 10.25 | |
Net Current Asset Value |
7.47 | 7.78 | 8.40 | 9.79 | |
EV/EBIT |
31.70 | 41.16 | 42.10 | 21.22 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
7.07% | 1.31% | 2.69% | 19.89% | |
Price to Operating Income |
34.74 | 45.19 | 46.88 | 23.61 | |
| Other line items | |||||
Average Receivables |
2.18 | 2.10 | 3.10 | 3.07 | |
Average Payables |
0.67 | 0.78 | 1.01 | 1.30 | |
Average Inventory |
2.92 | 2.92 | 2.79 | 3.39 | |
Average Assets |
11.82 | 12.43 | 12.79 | 14.01 | |
Average Common Equity |
9.09 | 9.39 | 10.00 | 10.78 |
Columns are period end dates